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in Species Extrapolation?
by Stephen C. Strom*
Introduction
My topic today is, Can in vitro studies assist us in
species extrapolation? And I'm going to narrow this
topic a little bit simply by concentrating on human data,
thinking that is the species that we're most interested
in. I would like to redefine the question and ask, Can
in vitro studies or in vivo-in vitro studies be used to
assess human genotoxicity?
I'd like to start with a quote from Dr. James Miller
and just read this for the group:
I do not think we can rely on extrapolation ofdata on chemical
carcinogens from experimental animnals to humans no matter
how sophisticated or plausible these extrapolations may seem,
until we know more about the chemical carcinogenesis in
humans.
There are a lot ofways to take this idea as the spring-
board for leading into the discussion, but I think one of
the most direct ways is to try to glean what we can
from the use of human cells in the short-term assays
and try to make species extrapolations based on the
short-term in vitro studies that one can do with human
cells. So the question that I'd like to address instead of
just, can in vitro studies be useful for risk assessment,
is to ask, Are human cells going to be useful for risk
assessment purposes?
I have an idea based on some of my own research and
research from many other laboratories that the answer
to that question might be yes. But today I will point
out the research that has been done and the rationale
for the types of studies that have been done so far.
This is a very timely topic, the use ofhuman cells for
carcinogenesis studies, as theJanuary 1 issue ofCancer
Research indicated. The cover showed Curtis Harris
and his collaborators, pioneers in the use ofhuman cells
and tissues in biomedical research (1). The protocol
which he uses, and basically all the other laboratories
that try to use human cells for carcinogenesis research
use, is to take whole animals and determine whether
compound X willinduce tumors, and ifso, at what sites?
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Then take the sites where the compound X induced
tumors and use tissues or isolated cells from those tis-
sues in a short-term assay to determine whether com-
pound Xinducesmutations, DNAdamage, DNArepair,
or any of a number of other end points for short-term
assays, such as induction of aneuploidy.
One can take all of the short-term tests that can be
done to assess genotoxicity, take the tissues from the
rodents or any other laboratory animal, explant those
tissues, and see what one can learn from the in vitro
estimates of genotoxicity to make an extrapolation
based on actual data from the in vitro studies back to
the in vivo studies, knowing full well that compound X
did induce tumors in the animal. To find out whether
compound X could induce tumors in the human, the
protocol is very simple. One would take the tissues of
interest from human donors and do exactly the same
types ofshort-term assays asone candowiththerodent
tissuestoinvestigate DNAdamage, DNArepair, muta-
genesis, or other short-term assays.
The types oftissues which are available for genotox-
icity research in short-term assays include most of the
epithelial tissues from the human, the tissues which are
the sites in the body where most cancer occurs. There-
fore, taking epithelial tissues and explanting those tis-
sues or isolating cells from those tissues for use in a
variety of short-term tests is useful.
In Curt Harris' review ofthis topic, he discussed the
techniques forexplantingthe epithelialtissues andindi-
catedthatcellsisolatedfrommanyofthesetissuescould
growinprimarycultureinaclonalmanner. Oneobvious
exception to that generality is the liver. I don't think
that there really is any cell culture methodology for
clonal growth ofrat or human liver currently available.
Butthe pointis that one canmakerisk assessment from
the short-term assays if one can scientifically and logi-
cally extrapolate in vitro studies back to the in vivo
situation. The suggestion I will use as a springboard
into the discussion for the entire group is that I believe
that human cells will be useful for risk assessment pur-
poses if certain criteria are met.
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data to in vivo would be valid if it can be determined
that the routes of metabolism of the chemical are the
same in vitro as in vivo, if the types of DNA adducts
produced are the same in culture as in vivo, ifthe cel-
lulardefense mechanisms suchasDNArepairpathways
are the same in vitro as invivo, etc. All ofthese param-
eters can be investigated to determine the validity of
the extrapolation of data from in vitro to in vivo with
animal models.
If it can be determined through investigations with
laboratory animals that for a particular chemical car-
cinogen, the routes of activation and detoxification of
the chemical by cells in vitro is similar or identical to
that observed when the investigations are conducted in
vivo, andifthespectrum ofadductsthatonecanidentify
on DNA isolated from a tissue from animals exposed to
a particular compound are the same as the types of
adducts one finds when cells from that tissue are
exposed tothe compound inculture, one has established
a scientific basis for making the extrapolation from in
vitro to in vivo for that laboratory animal.
To investigate the potential human genotoxicity, one
would have to rely heavily on the data from animal
models. For example, ifit was determined that rats of
a certain strain metabolize compound "A" in a manner
which results in a certain profile of adducts on hepa-
tocyte DNA, anditwasthendeterminedthatcompound
A induced liver tumors in that strain of rat, one could
investigate the routes of metabolism and the types of
DNA adducts produced on human hepatocytes exposed
in culture to compound A. Ifit were found that hepato-
cytes, isolated from a number of human cases, metab-
olized the compound in exactly the same way as the
rodent, and the same profile ofDNA adducts were pro-
duced by rodent and human hepatocytes, one would
have a scientific basis for concluding that there is a
potential for human genotoxicity from compound A.
Whether that potential is ever realized may depend on
the exposure of the initiated cells to tumor promoters
or other modifying factors. Since cancer is a multistep
process, which may involve induction of mutations,
chromosomalchanges, andtheresponse ofinitiatedcells
to tumor promoters, it may be unrealistic to believe
that any one short-term in vitro assay could faithfully
predict the carcinogenicity of all possible chemicals in
a whole animal. Just as one cannot measure the acti-
vation ofprotein kinase C with acyclic-AMP assay, one
willnotbe abletoaccurately predictthecarcinogenicity
ofchemicalswhich arenotmutagenswith amutagenesis
assay. Ifone simply understands the limitations ofeach
of the short-term assays, one can use that data in a
more meaningful way for risk assessment purposes.
I think that the use of human cells for the standard
types of genetic toxicology research is intuitively logi-
cal. There are certain situations where the short-term
assays are going to fall short ofbeing predictive offull
carcinogenesis. In particular, human cells may not
express the full biological response of exposure to car-
cinogens, e.g., transformation. This is an area where
short-term assays may fall short. However, this is not
just true with human cells but with cells from many
other species. Many tissues may not be useful for ini-
tiation-promotion protocols in vitro. And the multistep
aspects of carcinogenesis may be very hard to define
using only a single-cell type ofculture.
Theinterspeciesdifferencesincarcinogenmetabolism
and DNA adducts have been discussed in several
reviews and discussions (2-5). But I thinkthatthe gen-
eral consensus is that human cells in general form the
same types of metabolites as rat cells. There may be
quantitative differences in the amounts of specific
metabolites or specific DNA adducts produced bythese
two species, but not dramatic qualitative differences in
the exact types of metabolites that are produced or in
the exact types of adducts that are produced. Human
cells may also be used for risk assesesment purposes
for fine tuning the interpretation ofdata by asking at a
certainlevelofDNAadducts, Canoneexpecttoobserve
agenotoxicevent? asopposedtosimplyaskingtheques-
tion, Is this chemical going to be genotoxic in this spe-
cies?
The last point I'd like to discuss is the multistep area
of carcinogenesis and emphasize the newer areas of
research, including those involving oncogenes. Activat-
ed human oncogenes transform rat cells quite well.
Therefore, there may be common pathways to trans-
formation between the species. Ifone determined that
exposure to aparticular chemicalinduced the activation
ofoncogenes in the liver ofarat, that datamaybe very
relevant to the activation of those same oncogenes in
other species, including humans.
However, there are some aspects of carcinogenesis
researchthatcanonlybeaddressedwithhumantissues.
Whereas many rat or mouse cells seem to be trans-
formed quite well by transfection of oncogenes, when
one puts those same activated oncogenes into human
cells, theydon'tresultinthetransformation ofthe cells.
There are numerous examples ofthis in the literature.
Experiments have been reported in which mutated ras
genes, alone or in combination with other cooperating
genes such as the myc gene, have been transfected into
human cells (6). The phenotype that results from these
experiments with oncogene transfected human cells
indicatesthatthehumancellsaremoredifficulttotrans-
form with cloned oncogenes than the rodent cells, sug-
gestingthattheremaybe repressorgenesinthe human
cells that antagonize the action of the activated onco-
genes. Therefore, the full biological response to onco-
gene activation in human cells may be slightly different
thanthatobservedfollowingtheactivationofoncogenes
in rodent cells. In a situation such as this, one really
has to perform studies with human cells and directly
determine (possiblyonagene-by-genebasis)whichdata
fromexperiments performedwithrodentcells aregoing
to be directly relevant to humans.
I think at this point I'd like to stop and encourage
discussion from the floor. Are there any comments in
particular about the use ofhuman cells or reasons why
one should not use human cells for carcinogenesis
research?
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Discussion
DR. LUCIER: Isn't the key part of the process miss-
ing? That is, the great difficulty in producing transfor-
mations in human cells?
DR. STROM: That's animportantpoint. It's verylikely
that the full complement of biological responses that
one can measure in vivo are not going to be reproduced
in vitro in any short-term test. This is true with short-
term tests with rodent cells, also. This problem is not
unique to human cells. But I agree with you that the
problem is going to be getting complete transformation
ofcells in vitro.
DR. GEORGE LUCIER, NIEHS: Steve, for the kinds
of events that hormone or receptor-mediated events
mightbeimportant tothe process ofextrapolation, say,
estrogen action, and maybe to a lesser extent TCDD
action, people who have tried to culture cells, whether
it be animal or human, and look at these receptor
mediated events (and estrogen is probably the best
example) have found that the in vitro situation really
doesn't at all mimic the in vivo situation. The receptor
is often lost because you're dealing with a hormonal
milieu that's required, that you've taken away, that's
required for the maintenance of the receptor, and so
forth. For example, the receptor is lost in culture for
estrogen in either liver or reproductive tract tissues.
So people who have tried to develop invitro models and
use them for extrapolating for this or that have really
been stymied by this. It might be easier to do for the
more genotoxic events. It may be more difficult to do
forthose eventsthatinvolvethe endocrine system. And
I don't know if you care to comment on that, but it's
something that people like me who have tried to look
at estrogen action in vitro have been really blocked by.
DR. STROM: The comment is that cells in culture in
general may not be a particularly good model. You're
not saying that only human cells are not particularly
good in that regard. It's just that the in vitro systems
themseives do have some shortcomings. Is that the
point?
DR. LUCIER: Yeah. And particularly in regards to
events relating to the carcinogenic process that are
mediated through the endocrine system.
DR. STROM: I think that's a key point. Many of the
epithelial tissues have a tendency to dedifferentiate in
culture very rapidly and lose some ofthe differentiated
functions that they would have in vivo. And that's cer-
tainly a problem.
Again, I thinkunderstandingthe limits ofyour short-
tern assay and knowing what you can do with it and
what you can't do with it is important. It's very likely
that many ofthose things you brought up are not going
to be able to be done in culture until one determines
what the appropriate growth factors or substrates are
for these cells in culture.
And, again, the problem with the liver, which I'm
more familiarwith, is thatthere are certain ways to get
around some ofthese problems. With the liver one can
put compounds like phenobarbitol in culture and it
seems to maintain the viability of the cells up to many
weeks in certain instances. DMSO and coculture tech-
niques, when hepatocytes are maintained in culture
with liver epithelial cells, can prolongthe differentiated
state of these cells in culture for weeks to months. So
I think it's very likely that as cell culture techniques
are improved and more research is done, that even in
the tissues such as the endocrine tissues, one will be
able to prolong the viability and differentiated state of
many epithelial tissues in vitro.
UNKNOWN SPEAKER: Has anybody tried the use of
nude animals, that is, immunologically deficient ani-
mals, to compare the responses of human tissues as
tissues rather than as cells compared to animal cells as
a basis for species extrapolation at least oftoxic effect?
DR. STROM: Do you mean by transplantation of
human tissues into the nude mouse? Is that what you
mean?
UNKNOWN SPEAKER: Yes.
DR. STROM: I'm not aware ofthat being done on any
grand scale. There are certain instances where human
skin was put on the back of nude mice and someone
tried TPA promotion experiments. The situation is that
there are certain strains of mice that are easily pro-
moted by TPA and work well on initiation-promotion
protocols. Whereas, in other strains of mice, the initi-
ation-promotion protocol with TPA on the back of the
mouse skin doesn't work all that well. And when the
experiments were done with the human skin, TPA was
found to be a weakpromoter. I thinkthis points outthe
factthatworkwiththehumantissuesthemselvesreally
has to be done even ifit isn't in the transplant situation
inthenudemouse. Becausetherearecertaindifferences
that one sees between different species and their sus-
ceptibility to cancer. And it can only be addressed by
using that particular tissue. One can't predict a priori
what's going to happen unless you do the experiment
with human cells or tissues.
DR. BYRON BUTTERWORTH, CHEMICAL INDUSTRY
INSTITUTE OF TOXICOLOGY: I think that we've become
far too comfortable with our rodent models. We use
them a lot. We trust them. We publish all the time.
And I think it's very important that what Steve says,
that the kind of things that Steve has said get more
attention. Letmejustgiveyouoneexample. BillGreen-
lee showedme one article, which I thinkreallydeserves
further consideration. It was an epidemiological study
inwhich30yearsago, inaplantinNitro, WestVirginia,
there was a terrible accident and many people were
exposed to TCDD, 121 people. They all had chloracne,
and beyond that they had severe problems such as liver
enlargement, liver tenderness. And it lasted for more
than 4 years.
Thirtyyearslatertheydidafollow-upepidemiological
study, and there was no increase in the incidence of
cancer. Which raises the very, very frightening ques-
tion, Whyis a chemical that is so extraordinarilypotent
in the rodent not an obvious human carcinogen? And
the disturbing companion question is, Are there potent
human carcinogens that we're not recognizing because
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they're negative intherodentmodel? Sowhenwe asked
before what is the importance ofdetermining what the
mechanism is-is it cell proliferation, is it promotion
viareceptors-I thinkit'sveryimportantbecausethese
kinds of things may be the very points that will help
clarify the differences between species specificity. So
looking both at genotoxic events, metabolic activation,
and going beyond that looking at hormonal responses,
I think it's very, very important forus inthe real world
ofrisk assessment.
DR. MARSHALL ANDERSON, NIEHS: I hear what
you're saying. But is that really a fair comparison? Be-
cause I don't think the animal studies being done, like
with Henry Pitot's model, or in the skin with TCDD
where you have come in withjust one high dose. I think
in all of those studies it has been continuous low-level
exposure. I hear what you're saying, and I think it
would be interesting to go back. So tell Bill Greenlee
thathe shoulddothatexperimenttogobackwithPitot's
model. What are you shaking your head about?
DR. ANDERSON: Yeah. But they were spread. It was
one dose every 2 weeks. It was still spread over a long
time. Right?
UNKNOWN SPEAKER: Right; now he's doing it for 1
year. So 26 doses every other week is the dose. And
they're subcutaneous doses, so it's a very gradual re-
lease. So it's a chronic exposure situation.
UNKNOWN SPEAKER: That's right. The effect went
away. But I would add one otherthing to that comment
regarding TCDD. In the NTP study in the Kociba
study, I believe liver tumors were only seen in female
rats. Isthatright? AndtheindividualsinWestVirginia,
were they mostly males?
UNKNOWN SPEAKER: But in the rat. In the most it
was a little bit different. In the rat, the Kociba study
and the NTP study exhibited liver tumors only in the
male animals.
UNKNOWN SPEAKER: I'm sure. Is he still here? Dr.
Kociba? That's too bad. But in any event, there was a
clear sex difference and it was reversed in the mice, the
liver tumors. And the point is that it relates back to the
invitro studiesthat, inadditiontootherkinds ofthings,
we have to look at the sex difference as well. And that
relates to something I'm interested, of course, the en-
docrine differences in the extrapolation process of re-
constituting those kind of systems where I think we
have to be concerned about sex difference as well as
responsiveness.
DR. STROM: I think one of the key points that I've
heard today over and over again now is: Is an in vitro
assay predictive ofin vivo genotoxicity? I think we can
turn that around a little bit for purposes ofthis discus-
sion and say, Are in vivo toxicity studies done with one
species predictive of the next species? And I think I'd
like to ask Dr. Tennant that if I might.
As I recall, 50 to 70% of the chemicals that were
identified as mutagens in some sort ofan in vitro study
end up being carcinogens in the whole animal in one
species or another. Then one takes that data and asks,
What is the correlation between carcinogenicity in mice
and rats?
DR. TENNANT: 75%.
DR. STROM: Okay. So it does improve a bit. So bas-
ically, ifone uses as the gold standard the in vivo bioas-
say, one is still left with the interspecies extrapolation
that only improves about 20% from the in vitro studies.
And when one comes up with a compound that can in-
duce tumors in mice or rats and we're trying to ex-
trapolate it to humans, we have to determine whether
we are mice or rats. And some of the ways, as Dr.
Butterworth has said, that this might be done is to look
at the mechanistic approach. Do they make the same
metabolites? Do they make the same adducts? Are they
repaired at the same rate? And so on, with everything
that may affect the carcinogenicity of the compound,
including cell turnover. Experiments can then be done
to address these points to make the interspecies ex-
trapolation. But, again, the interspecies extrapolation
is probably only as good as the data that one can get in
the short-term assays.
DR. ALBERT: We'll move on to the next area, which
is, How do we predict toxicity of complex mixtures?
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